Cervicitis

Microbix Presents Results of STI Test Controls at ASM Microbe

Retrieved on: 
Tuesday, June 13, 2023
Pelvic inflammatory disease, STI, Infection, QAP, Infertility, Urethritis, AMR, RUO, Buffer, Mycoplasma genitalium, OTCQX, IVD, TSX, Poster, Cervicitis, American Society for Microbiology, Society, Vaccine, MGEN

At ASM Microbe, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.

Key Points: 
  • At ASM Microbe, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.
  • Microbix will thereby showcase its ever-growing portfolio of QAPs that help ensure the accuracy of antigen and nucleic acid (i.e., “PCR”) tests and their workflows.
  • Using innovative and proprietary methods, Microbix created and manufactured such materials – including for five AMR variants of Mgen.
  • Formatted onto COPAN® FLOQSwabs®, the resulting Microbix QAPs were then used to validate and support novel tests for AMR detection, namely the SpeeDx Pty.

New CDC Guidelines Endorse Opt-Out Screening for Two of the Most Common Sexually Transmitted Infections (STIs), Recommend Nucleic Acid Testing for Mycoplasma Genitalium

Retrieved on: 
Monday, July 26, 2021
Medical devices, Medical Supplies, Women, Infectious diseases, Biotechnology, AIDS, Health, Consumer, General Health, Sexually transmitted diseases and infections, Medical specialties, Clinical medicine, Infectious causes of cancer, Medicine, Mycoplasma, Synthetic biology, Mycoplasma genitalium, Urethritis, Cervicitis, Nucleic acid test, Protein M

For the first time, CDC guidelines also defined specific populations (men with recurrent urethritis and women with recurrent cervicitis) to be tested for Mycoplasma genitalium and recommended nucleic-acid amplification testing (NAAT) for detection.

Key Points: 
  • For the first time, CDC guidelines also defined specific populations (men with recurrent urethritis and women with recurrent cervicitis) to be tested for Mycoplasma genitalium and recommended nucleic-acid amplification testing (NAAT) for detection.
  • The 2015 CDC guidelines included M. genitalium as an emerging issue, but no FDA-cleared NAATs were available at that time11.
  • Hologic was first to market in 2019 with a NAAT for M. genitalium, and Hologics Aptima Mycoplasma genitalium Assay is specifically noted in the current guidelines1.
  • No FDA-cleared M. genitalium tests are available in the U.S. that detect antibiotic resistance, although Hologic is working to develop one.

Pelvic Exams Do Not Help Diagnose STDs In Adolescent Girls, Study Says

Retrieved on: 
Tuesday, July 3, 2018
Sexually transmitted diseases and infections, Medicine, RTT, Mycoplasma, Bacteria, Clinical medicine, Chlamydia infections, Infections with a predominantly sexual mode of transmission, Pelvic inflammatory disease, Pelvic examination, Cervicitis, Sexually transmitted infection

"Pelvic exams lack reliability and provide very little new information when compared with other methods of diagnosis.

Key Points: 
  • "Pelvic exams lack reliability and provide very little new information when compared with other methods of diagnosis.
  • The pelvic exam information did not consistently help the physicians better identify whether the patient was STD positive or negative, the study found.
  • The study, " The Additive Value of Pelvic Exams to History in Predicating Sexually Transmitted Infections for Adolescent Females with Suspected Cervicitis or Pelvic Inflammatory Disease ," confirmed that pelvic exams do not increase the sensitivity or specificity of diagnosis.
  • Practitioners may choose to perform pelvic exams, because urine test results are not immediately available, the study authors note.